Logo

BMS’s Breyanzi (lisocabtagene maraleucel) Receive CHMP Positive Opinion for the Treatment of Multiple Indications

Share this

BMS’s Breyanzi (lisocabtagene maraleucel) Receive CHMP Positive Opinion for the Treatment of Multiple Indications

Shots:

  • The EMA’s CHMP has adopted a positive opinion recommending approval of Breyanzi (CD19-directed CAR T cell therapy) in patients with r/r DLBCL, PMBCL & FL3B after 2+ lines of systemic therapy. The EC’s decision is expected within 67 days
  • The opinion is based on a (TRANSCEND NHL 001) & (TRANSCEND WORLD study) of Breyanzi in patients with r/r DLBCL & 2 others indications who received Breyanzi in the inpatient & outpatient setting
  • The EC’s decision will apply to all EU member states, Iceland, Norway & Liechtenstein. Breyanzi was approved in the US for r/r large B-cell lymphoma including DLBCL, primary mediastinal large B-cell lymphoma, FL3B & is also approved in Japan for r/r LBCL & FL

Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions